Athena Heart — [310]

: Conduct regular ECGs to monitor for potential proarrhythmic effects or excessive QT prolongation.

: Monitor serum creatinine levels; small increases are common but should be assessed if they persist.

: Do not use in patients who cannot or will not be converted to sinus rhythm. ATHENA HEART [310]

: The trial established dronedarone as a rhythm-control therapy specifically aimed at reducing clinical complications rather than just maintaining sinus rhythm. 2. Dronedarone (Multaq) Usage Guide

Patients with paroxysmal or persistent AF or AFL who are in sinus rhythm or who will be cardioverted. : Conduct regular ECGs to monitor for potential

It is intended to reduce the risk of hospitalization for AF. 3. Safety and Contraindications

Clinicians should monitor several factors to prevent adverse outcomes: : The trial established dronedarone as a rhythm-control

: To determine if dronedarone could lower the risk of hospitalization due to cardiovascular events or death from any cause in patients with atrial fibrillation (AF) or atrial flutter (AFL).